EVIDENT Completes Acquisition of CrestOptics

The acquisition expands Evident’s life science imaging portfolio and strengthens its capabilities in high-speed, high-content 3D imaging for research, pharmaceutical and biotech applications.

Evident and CrestOptics have worked together for several years, with CrestOptics’ spinning disk technology already used in Evident’s microscope systems. The acquisition will strengthen and expand their existing partnership.

Read More:RASA World Raises $9.5 Million in funding from Bullpen Capital

CrestOptics will continue operating from its headquarters, R&D and manufacturing facility in Rome. The company will also maintain its existing partnerships and distribution network while continuing to provide technology to the wider microscopy industry.

"Researchers are asking harder questions of increasingly complex biological models, and that demands faster, gentler, higher-resolution imaging," said Wes Pringle, Evident CEO. "Our customers push the limits of science, and our role is to advance the optical technologies that make new discoveries faster and easier than ever.

"Joining Evident is a natural next step for CrestOptics," said Renato Giacobbo Scavo, Chief Executive Officer, CrestOptics. "We share a commitment to advancing what microscopy can reveal. With Evident's global reach, manufacturing strength and applications expertise, we can accelerate our innovation roadmap and bring our technologies to many more laboratories worldwide.

About CrestOptics

Founded in 2011 in Rome, Italy, CrestOptics develops, and manufactures advanced optical imaging systems for life science research. Its spinning disk confocal and super resolution SIM technologies provide fast high contrast imaging with low phototoxicity, helping researcher's study live cells, 3D models, and thick tissues.

Read More:Henrico-based At Home Harmony Secures $5M in Funding